<div>
  <ul>
    <li>
      <p>
        Massachusetts-based antibody drug developer Nabla Bio has raised USD 26 million in a Series A round led by Radical Ventures, with contributions from all existing investors. It also announced partnerships with AstraZeneca, Bristol Myers Squibb Company, and Takeda, with potential earnings surpassing USD 550 million in upfront and milestone payments and royalties.
      </p>
    </li>
    <li>
      <p>
        Nabla Bio plans to use the acquired funds to accelerate its drug development efforts, focusing primarily on antibodies targeting multipass membrane proteins. The capital will go toward the company&rsquo;s research in creating solutions for hard-to-drug targets and complex cellular processes. 
      </p>
    </li>
    <li>
      <p>
        Nabla Bio is a biotech company that leverages AI to design antibodies for challenging diseases. The company's AI platform combines AI with massively parallel experimentation to design antibody therapeutics, primarily targeting complex multipass membrane proteins like G protein-coupled receptors (GPCRs) and ion channels. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20240514763517/en/Nabla-Bio-Secures-26M-Series-A-Financing-and-Collaborations-with-AstraZeneca-Bristol-Myers-Squibb-and-Takeda-for-Generative-Protein-Design">
      Press release
    </a>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

<div>
<p>Massachusetts-based antibody drug developer Nabla Bio has secured USD 26 million in a Series A funding round led by Radical Ventures, with further participation from all existing investors. The company also revealed partnerships with AstraZeneca, Bristol Myers Squibb Company, and Takeda, promising potential earnings more than USD 550 million in upfront and milestone payments as well as royalties.</p>

<p>The funds raised will be utilized by Nabla Bio to expedite its drug development projects, mainly concentrating on antibodies that target multipass membrane proteins. The investment will be used in advancing the company’s research for formulating solutions to tackle difficult-to-drug targets and intricate cellular processes.</p>

<p>Nabla Bio is a biotechnology firm that uses AI to develop antibodies for treating tough diseases. The company's AI platform merges AI with massively parallel experimentation to design antibody therapeutics, mainly committing to complex multipass membrane proteins like G protein-coupled receptors (GPCRs) and ion channels.</p>
</div>

Nabla Bio raises USD 26 million in Series A funding; signs three Big Pharma deals

Novel therapies to reboot cells and organs

Cell & Gene Therapy

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>Bristol-Myers Squibb's CAR T therapy, Breyanzi, has been approved by the FDA to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have relapsed or become refractory. These are types of non-Hodgkin lymphomas.</p>
 <p>Breyanzi is a one-time treatment that involves an infusion of CAR-positive viable T-cells, which are personalized for each patient. The therapy is designed for patients who have tried at least two prior treatment regimens. Key features of Breyanzi include its ability to create deep and long-lasting responses, its effectiveness in patients who haven't responded to standard care, and its established safety profile.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> Breyanzi is not a new name in the market and has been available since the FDA approved it in February 2021 for treating relapsed or refractory large B-cell lymphoma in adults, after two or more lines of systemic therapy. In June 2022, the FDA promoted Breyanzi enabling it to be used after one line of therapy. The drug has a current price of USD 487,477, rising from the original price tag of USD 410,300. The latest approval is a testament to the capabilities and potential of Breyanzi in treating various disease indications.&nbsp;</p>

Bristol-Myers receives FDA approval for Breyanzi to treat non-Hodgkin lymphomas

<div>
 
 <p>VantAI, a GenAI drug discovery company, is partnering with Bristol Myers Squibb (BMS) in a strategic collaboration. Their joint goal is to develop new molecular glues that can be used on various therapeutic targets.</p>
 <p>VantAI stands to receive up to USD 674 million in payments covering discovery, development, clinical, regulatory, and sales milestones. There will also be specific, tiered royalty payments. If successful, there is potential to expand the partnership further into more therapeutic programs from BMS.</p>
 <p>The combination of VantAI's geometric deep learning technologies with BMS' protein degradation expertise will be used to create the molecular glues. These will work to stabilize interactions between proteins.</p>
 <p>VantAI was established in 2019 with a focus on integrating GenAI and drug discovery. It develops computational models to expose unseen connections between molecules, diseases, and targets, effectively making protein interactions programmable. VantAI's geometric deep learning platforms are used specifically to concentrate on induced proximity modulators. These are used to fully unlock the potential of proximity modulator modalities for drug discovery.</p>
 
</div>

VantAI signs USD 674 million GenAI deal with Bristol Myers Squibb

<div>
 <p>AI biotech firm Terray Therapeutics, based in California, has initiated a multi-target collaboration with Bristol Myers Squibb (BMS) for discovering and manufacturing innovative small molecule therapeutics. Terray is set to receive an initial payment alongside potential milestone payments associated with preclinical, clinical, and sales stages, and also royalties from sales of any produced products. BMS will manage the development and commercialization after Terray's tNova platform is used to discover and create small molecule compounds for specific targets identified by BMS.</p>
</div>

Terray Therapeutics and Bristol Myers collaborate to develop small-molecular therapeutics

<div>
 
 <p>Bristol-Myers Squibb (BMS) has received manufacturing and marketing approval in Japan for Abecma (idecabtagene vicleucel) for the treatment of relapsed or refractory multiple myeloma (RRMM). The treatment is already approved in the US and EU regions. Abecma marks the first CAR T therapy to receive approval to be used in earlier lines of therapy for RRMM in Japan.</p>
 <p>Abecma is a CAR T-cell immunotherapy that targets the B-cell maturation antigen (BCMA). It is for RRMM patients who have undergone at least two previous treatments. Abecma's effectiveness was supported by data from an international Phase III clinical trial, KarMMa-3.</p>
 <p>Abecma showed improvements in median progression-free survival (mPFS), reducing disease progression or death risk. The overall response rate (ORR) was higher with Abecma compared to standard treatments. BMS believes this drug is a crucial addition to limited treatment options for RRMM patients.</p>
 
</div>

BMS’ multiple myeloma drug Abecma approved in Japan

<div>
  <ul>
    <li>
      <p>Bristol Myers Squibb and 2seventy bio's application for extended approval of their CAR T drug, Abecma, for multiple myeloma is undergoing an FDA advisory panel review, causing a delay in the approval decision.</p>
    </li>
    <li>
      <p>The extended approval is based on survival data from the KarMMA-3 clinical study, which suggests that Abecma can suppress multiple myeloma for longer periods compared to standard drug regimens.</p>
    </li>
    <li>
      <p>Both Bristol Myers Squibb and 2seventy bio believe that this extended approval for Abecma's use at an earlier stage in treatment can increase the drug's sales. Regulatory agencies in Japan, the European Union, and Switzerland are also reviewing this expanded use of Abecma.</p>
    </li>
  </ul>
</div>

FDA delays decision on BMS-2seventy bio’s Abecma approval expansion application

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

DISRUPTOR_PRESENT

<div>
 <ul>
  <li><p>Genetic testing and bioinformatics company Tempus has partnered with pharmaceutical company Bristol Myers Squibb for strategic cancer research. The collaboration aims to identify and validate new drug targets using multimodal datasets, computational approaches, and disease models derived from patients.</p></li>
  <li><p>The research will focus on finding options for patients who have no effective therapies or are unresponsive to current treatments. The teams will analyze disease cohorts and utilize Tempus' multimodal database and patient-derived organoids for iterative testing of potential targets.</p></li>
 </ul>
</div>

Tempus collaborates with Bristol Myers Squibb for cancer research using AI

Bristol-Myers Squibb is acquiring precision medicine drugmaker Mirati Therapeutics for up to $5.8 billion. The deal values Mirati at $4.8 billion in equity and $3.7 billion in enterprise value. Mirati shareholders will also receive a contingent value right (CVR) that offers a potential one-time cash payment of $12.00 per share, totaling around $1.0 billion. The acquisition will diversify Bristol's oncology business and help offset anticipated revenue losses from upcoming patent expirations. The deal is expected to close by 1H 2024, subject to customary closing conditions, including shareholder and regulatory approvals.

All Updates

Nabla Bio raises USD 26 million in Series A funding; signs three Big Pharma deals

Bristol-Myers receives FDA approval for Breyanzi to treat non-Hodgkin lymphomas

VantAI signs USD 674 million GenAI deal with Bristol Myers Squibb

Terray Therapeutics and Bristol Myers collaborate to develop small-molecular therapeutics

BMS’ multiple myeloma drug Abecma approved in Japan

FDA delays decision on BMS-2seventy bio’s Abecma approval expansion application

Tempus collaborates with Bristol Myers Squibb for cancer research using AI

Bristol-Myers Squibb to acquire Mirati for up to of USD 5.8 billion

MEDiC Life Sciences partners with Bristol-Myers Squibb to advance oncology discovery programs

Foundation Medicine partners with BMS to develop FoundationOne CDx

AI Drug Discovery

Nabla Bio raises USD 26 million in Series A funding; signs three Big Pharma deals

Contact us